OncLive News Network: On Location at ESMO 2023 - Episode 3
Gathering Insights in Gastrointestinal Cancers From ESMO 2023: Dr Pietrantonio
OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.
Today-
We are reporting from the 2023 ESMO Congress!
Get ready for highlights of some of the top news presented each day during the meeting—and soon we’ll speak with Dr Filippo Pietrantonio to discuss some new data in gastrointestinal cancer.
Welcome to OncLive News Network! I’m Caroline Seymour.
Findings from the phase 3 CodeBreaK 300 trial (NCT05198934) showed that the combination of sotorasib (Lumakras) and panitumumab (Vectibix) led to a significant improvement in progression-free survival (PFS) vs standard of care chemotherapy in patients with chemotherapy refractory KRAS G12C–mutant metastatic colorectal cancer. Moreover, the combination was tolerable and resulted in lower rates of grade 3 or greater treatment-related adverse effects vs standard of care therapy.
In the phase 3 KEYNOTE-671 trial (NCT03425643), neoadjuvant therapy with pembrolizumab (Keytruda) plus chemotherapy followed by resection and adjuvant pembrolizumab produced a statistically significant improvement in overall survival (OS) compared with neoadjuvant chemotherapy and resection alone in patients with resectable stage II, IIIA, or IIIB (N2) non–small cell lung cancer. Median OS was not reached (NR) (95% CI NR-NR) in the pembrolizumab arm vs 52.4 months (95% CI 45.7-NR) in the placebo arm, reflecting a 28% reduction in the risk of death.
Finally, in results from the phase 3 PSMAfore trial (NCT04689828), treatment with 177Lu-PSMA-617 (LuPSMA; lutetium Lu 177 vipivotide tetraxetan; Pluvicto) prolonged radiographic PFS (rPFS) vs an androgen pathway receptor inhibitor change in taxane-naive patients with PSMA-positive metastatic castration-resistant prostate cancer, with a favorable safety profile. At a median follow-up of 15.9 months, the hazard ratio for rPFS was 0.43 in favor of the radioligand therapy.
Please be sure to check out more of our coverage from the 2023 ESMO Congress at OncLive.com.
That’s all for today. Tomorrow, we’ll sit down with Drs Jacob Sands, Ignace Vergote, Paolo Tarantino, and Yelena Janjigian, who will share their perspectives on breaking research in lung, gynecologic, breast, and gastrointestinal cancers.
Thank you for watching OncLive News Network: On Location, I’m Caroline Seymour.